Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 285

1.

Potent inhibition of angiogenesis by the IGF-1 receptor-targeting antibody SCH717454 is reversed by IGF-2.

Bid HK, Zhan J, Phelps DA, Kurmasheva RT, Houghton PJ.

Mol Cancer Ther. 2012 Mar;11(3):649-59. doi: 10.1158/1535-7163.MCT-11-0575. Epub 2011 Dec 21.

2.

Dual targeting of the type 1 insulin-like growth factor receptor and its ligands as an effective antiangiogenic strategy.

Bid HK, London CA, Gao J, Zhong H, Hollingsworth RE, Fernandez S, Mo X, Houghton PJ.

Clin Cancer Res. 2013 Jun 1;19(11):2984-94. doi: 10.1158/1078-0432.CCR-12-2008. Epub 2013 Apr 2.

3.

Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.

Huang SW, Lien JC, Kuo SC, Huang TF.

Carcinogenesis. 2012 May;33(5):1022-30. doi: 10.1093/carcin/bgs127. Epub 2012 Mar 20.

PMID:
22436611
4.

The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma.

Kurmasheva RT, Dudkin L, Billups C, Debelenko LV, Morton CL, Houghton PJ.

Cancer Res. 2009 Oct 1;69(19):7662-71. doi: 10.1158/0008-5472.CAN-09-1693. Epub 2009 Sep 29.

5.

L-5F, an apolipoprotein A-I mimetic, inhibits tumor angiogenesis by suppressing VEGF/basic FGF signaling pathways.

Gao F, Vasquez SX, Su F, Roberts S, Shah N, Grijalva V, Imaizumi S, Chattopadhyay A, Ganapathy E, Meriwether D, Johnston B, Anantharamaiah GM, Navab M, Fogelman AM, Reddy ST, Farias-Eisner R.

Integr Biol (Camb). 2011 Apr;3(4):479-89. doi: 10.1039/c0ib00147c. Epub 2011 Feb 1.

6.

R1507, an anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, and EWS/FLI-1 siRNA in Ewing's sarcoma: convergence at the IGF/IGFR/Akt axis.

Huang HJ, Angelo LS, Rodon J, Sun M, Kuenkele KP, Parsons HA, Trent JC, Kurzrock R.

PLoS One. 2011;6(10):e26060. doi: 10.1371/journal.pone.0026060. Epub 2011 Oct 11.

7.

Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma.

Wang Z, Chakravarty G, Kim S, Yazici YD, Younes MN, Jasser SA, Santillan AA, Bucana CD, El-Naggar AK, Myers JN.

Clin Cancer Res. 2006 Aug 1;12(15):4755-65.

8.

NADPH oxidase 4 mediates insulin-stimulated HIF-1α and VEGF expression, and angiogenesis in vitro.

Meng D, Mei A, Liu J, Kang X, Shi X, Qian R, Chen S.

PLoS One. 2012;7(10):e48393. doi: 10.1371/journal.pone.0048393. Epub 2012 Oct 29.

9.

Endothelium-derived nitric oxide (NO) activates the NO-epidermal growth factor receptor-mediated signaling pathway in bradykinin-stimulated angiogenesis.

Moraes MS, Costa PE, Batista WL, Paschoalin T, Curcio MF, Borges RE, Taha MO, Fonseca FV, Stern A, Monteiro HP.

Arch Biochem Biophys. 2014 Sep 15;558:14-27. doi: 10.1016/j.abb.2014.06.011. Epub 2014 Jun 21.

PMID:
24960080
10.
11.

Dual IGF-I/II-neutralizing antibody MEDI-573 potently inhibits IGF signaling and tumor growth.

Gao J, Chesebrough JW, Cartlidge SA, Ricketts SA, Incognito L, Veldman-Jones M, Blakey DC, Tabrizi M, Jallal B, Trail PA, Coats S, Bosslet K, Chang YS.

Cancer Res. 2011 Feb 1;71(3):1029-40. doi: 10.1158/0008-5472.CAN-10-2274. Epub 2011 Jan 18.

12.

Anti-angiogenic activity of a small molecule STAT3 inhibitor LLL12.

Bid HK, Oswald D, Li C, London CA, Lin J, Houghton PJ.

PLoS One. 2012;7(4):e35513. doi: 10.1371/journal.pone.0035513. Epub 2012 Apr 17.

13.

Selective inhibition of SCLC growth by the A12 anti-IGF-1R monoclonal antibody correlates with inhibition of Akt.

Yeh J, Litz J, Hauck P, Ludwig DL, Krystal GW.

Lung Cancer. 2008 May;60(2):166-74. Epub 2007 Nov 14.

PMID:
18006183
14.

A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity.

Dong J, Sereno A, Aivazian D, Langley E, Miller BR, Snyder WB, Chan E, Cantele M, Morena R, Joseph IB, Boccia A, Virata C, Gamez J, Yco G, Favis M, Wu X, Graff CP, Wang Q, Rohde E, Rennard R, Berquist L, Huang F, Zhang Y, Gao SX, Ho SN, Demarest SJ, Reff ME, Hariharan K, Glaser SM.

MAbs. 2011 May-Jun;3(3):273-88. Epub 2011 May 1.

15.

A potent anti-HB-EGF monoclonal antibody inhibits cancer cell proliferation and multiple angiogenic activities of HB-EGF.

Sato S, Drake AW, Tsuji I, Fan J.

PLoS One. 2012;7(12):e51964. doi: 10.1371/journal.pone.0051964. Epub 2012 Dec 14.

16.

Fisetin inhibits various attributes of angiogenesis in vitro and in vivo--implications for angioprevention.

Bhat TA, Nambiar D, Pal A, Agarwal R, Singh RP.

Carcinogenesis. 2012 Feb;33(2):385-93. doi: 10.1093/carcin/bgr282. Epub 2011 Dec 1.

PMID:
22139440
17.

Endothelial monocyte activating polypeptide II interferes with VEGF-induced proangiogenic signaling.

Awasthi N, Schwarz MA, Verma V, Cappiello C, Schwarz RE.

Lab Invest. 2009 Jan;89(1):38-46. doi: 10.1038/labinvest.2008.106. Epub 2008 Nov 10.

18.

Orally Administered Mucolytic Drug l-Carbocisteine Inhibits Angiogenesis and Tumor Growth in Mice.

Shinya T, Yokota T, Nakayama S, Oki S, Mutoh J, Takahashi S, Sato K.

J Pharmacol Exp Ther. 2015 Sep;354(3):269-78. doi: 10.1124/jpet.115.224816. Epub 2015 Jun 30.

19.

Novel nuclear localization and potential function of insulin-like growth factor-1 receptor/insulin receptor hybrid in corneal epithelial cells.

Wu YC, Zhu M, Robertson DM.

PLoS One. 2012;7(8):e42483. doi: 10.1371/journal.pone.0042483. Epub 2012 Aug 3.

20.

CAPE suppresses VEGFR-2 activation, and tumor neovascularization and growth.

Chung TW, Kim SJ, Choi HJ, Kwak CH, Song KH, Suh SJ, Kim KJ, Ha KT, Park YG, Chang YC, Chang HW, Lee YC, Kim CH.

J Mol Med (Berl). 2013 Feb;91(2):271-82. doi: 10.1007/s00109-012-0952-6. Epub 2012 Aug 31.

PMID:
22935775

Supplemental Content

Support Center